4DX Medical (ASX:4DX), a company now offering next-gen lung scanning technology to the U.S. markets (and still hot after a recent FDA approval for that jurisdiction) soared above the $2/sh mark out the gate on Monday trades, spurred by a fresh announcement that sent its shares another +30% higher – making this company just about the most meteoric play on the bourse in recent memory.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
On Monday, the company confirmed its executed a series of agreements with both Australia and Brazil. In the former case, 4DX will work with a private entity called Spectrum Medical Imaging to assist delivery of the Australian National Lung Cancer Screening Program (NLCSP), which the company says ultimately will allow for something of a revolution in lung imaging.
Elsewhere, the company will introduce its tech to Royal Melbourne Hospital.
Secondly, the company is also listing a lung screening program in Brazil, alongside an unnamed global pharma player, which also focuses on lung cancer and other coronary artery issues.
While not related to the FDA approval, Monday’s reaction – widely perceived to be sitting on the cusp of gamechanging medical tech – is clear indication of a market confident this stock’s got more to run.
“4DMedical is committed to Australian healthcare, and is excited to support the National Lung Cancer Screening Program – this is a key piece of Australian healthcare infrastructure and we believe our suite of products can play a big role,” company chief Andreas Fouras said.
“I am excited to have Royal Melbourne Hospital as the first Australian public hospital and Academic Medical Centre to roll out the 4DMedical suite, further extending the reach of our technology into frontline clinical practice.”
4DX last traded at $2/sh intraday.
Join the discussion: See what HotCopper users are saying about 4DX Medical Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.